Myocarditis and carotidynia caused by Granulocyte-Colony stimulating factor administration

References

• Neulasta (Pegfilgrastrim) Labelling. Full prescribing information. Thousand Oaks (CA): Amgen Inc; 2018.
   Google Scholar
• D’Souza A, Jaiyesimi I, Trainor L, et al. Granulocyte colony–stimulating factor administration: adverse events. Transfus Med Rev. 2008;22(4):280–290.
   PubMedGoogle Scholar
• Gertz MA, Lacy MQ, Bjornsson J, et al. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res. 2000;9(5):635–643.
   Google Scholar
• O’Malley DP, Whalen M, Banks PM, et al. Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. Am J Hematol. 2003;73(4):294–295.
   Web of Science ®Google Scholar
• Darie C, Boutalba S, Fichter P, et al. Aortite après injections de G-CSF. La Revue de Médecine Interne. 2004;25(3):225–229.
   Google Scholar
• Adiga GU, Elkadi D, Malik SK, et al. Abdominal aortitis after use of granulocyte colony-stimulating factor. Clin Drug Invest. 2009;29(12):821–825.
   Web of Science ®Google Scholar
• Miller EB, Grosu R, Landau Z, et al. Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF). Clin Rheumatol. 2016; 35(6):1655–1657.
   Web of Science ®Google Scholar
• Sato Y, Kaji S, Ueda H, et al. Thoracic aortitis and aortic dissection following pegfilgrastim administration. Euro J Cardio-Thoracic Sur. 2017; 52(5):993–994.
   Web of Science ®Google Scholar
• Kinjo Y, Kurita T, Ueda T, et al. Acute arteritis after G-CSF administration. Int Canc Conf J. 2019;8(2):77–80.
   Web of Science ®Google Scholar
• Parodis I, Dani L, Notarnicola A, et al. G-CSF-induced aortitis: two cases and review of the literature. Autoimmun Rev. 2019; 18(6):615–620.
   PubMed Web of Science ®Google Scholar
• Hiranuma K, Kusunoki S, Fujino K, et al. Drug-induced aortitis in a patient with ovarian cancer treated with bevacizumab combination therapy. Taiwan J Obstet Gynecol. 2018;57(5):750–752.
   PubMed Web of Science ®Google Scholar
• Hayashi S, Maruoka S, Takahashi N, et al. Carotidynia after anticancer chemotherapy. Singapore Med J . 2014;55(09):e142–e144.
   Google Scholar
• Tomoyuki M, Shinichiro K, et al. Aortitis which developed after the administration of granulocyte-colony stimulating factor. Modern Rheumatol Case Reports. 2019;4:1–5.
   Google Scholar
• Hideko H, Hiroyuki T, et al. Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature. BMC Cancer. 2019;1:1217.
   Google Scholar
• Oshima Y, Takahashi S, Tani K, et al. Granulocyte colony-stimulating factor-associated aortitis in the Japanese adverse drug event report database. Cytokine. 2019;119:47–51.
   PubMed Web of Science ®Google Scholar
• Lardieri A, McCulley L, Christopher Jones S, et al. Granulocyte colony-stimulating factors and aortitis: a rare adverse event. Am J Hematol. 2018;93(10):E333–E336.
   PubMed Web of Science ®Google Scholar
• van der Bogt KEA, Palm WM, Hamming JF, et al. Carotidynia: a rare diagnosis in vascular surgery practice. EJVES Extra. 2012;23(2):e18–e19.
   Google Scholar
• Second Headache Classification Subcommittee of the International Headache Society. Classification and diagnosis criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 2004;24:70–71.
   Google Scholar
• Lucas Junior A, Ferreira LA, Fernandes BE, et al. Carotidynia: a case report with clinical and imaging follow up. J Neurol Neurosci. 2016;7(5):148.
   Google Scholar
• Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology. 2015;54(3):463–470.
   PubMed Web of Science ®Google Scholar
• Umeda M, Ikenaga J, Koga T, et al. Giant cell arteritis which developed after the administration of granulocyte-colony stimulating factor fir cyclic neutropenia. Intern Med. 2016;55(16):2291–2294.
   Web of Science ®Google Scholar
• Sait MR, Lepore M, Kwasnicki R, et al. The 2016 revised ACR criteria for diagnosis of giant cell arteritis – Our case series: can this avoid unnecessary temporal artery biopsies? International Journal of Surgery. 2017;9:19–23.
   Web of Science ®Google Scholar
• Sagar S, Liu PP, Cooper LT, et al. Myocarditis. Lancet (London, England). 2012;379(9817):738–747.
   PubMed Web of Science ®Google Scholar
• Wu L, Diny NL, Ong S, et al. Pathogenic IL-23 signaling is required to initiate GM-CSF-driven autoimmune myocarditis in mice. Eur J Immunol. 2016;46(3):582–592.
   Web of Science ®Google Scholar
• Hill JM, Syed MA, Arai AE, et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol. 2005;46(9):1643–1648.
   PubMed Web of Science ®Google Scholar
• Steinwender C, Hofmann R, Kypta A, et al. Late stent thrombosis after transcoronary transplantation of granulocyte-colony stimulating factor-mobilized peripheral blood stem cells following primary percutaneous intervention for acute myocardial infarction. Int J Cardiol. 2007;122(3):248–249.
   Web of Science ®Google Scholar
• Canales MA, Arrieta R, Gomez-Rioja R, et al. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. J HematotherStem Cell Res. 2002;11(4):675–681.
   Google Scholar
• McGeachy MJ. GM-CSF: the secret weapon in the TH17 arsenal. Nat Immunol. 2011;12(6):521–522.
   PubMed Web of Science ®Google Scholar
• Chen G, Bracamonte-Baran W, Diny NL, et al. Sca-1+ cardiac fibroblasts promote development of heart failure. Eur J Immunol. 2018;48(9):1522–1538.
   Web of Science ®Google Scholar
• El-Behi M, Ciric B, Dai H, et al. The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol. 2011;12(6):568–575.
   PubMed Web of Science ®Google Scholar